These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25438764)

  • 1. Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant.
    Azmi F; Ahmad Fuaad AA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Bioorg Med Chem; 2014 Nov; 22(22):6401-8. PubMed ID: 25438764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship.
    Zaman M; Abdel-Aal AB; Fujita Y; Phillipps KS; Batzloff MR; Good MF; Toth I
    PLoS One; 2012; 7(1):e30146. PubMed ID: 22253911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery.
    Skwarczynski M; Toth I
    Methods Mol Biol; 2011; 751():297-308. PubMed ID: 21674338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
    J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand.
    Abdel-Aal AB; El-Naggar D; Zaman M; Batzloff M; Toth I
    J Med Chem; 2012 Aug; 55(15):6968-74. PubMed ID: 22800462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Method for the synthesis of highly pure vaccines using the lipid core peptide system.
    Moyle PM; Olive C; Good MF; Toth I
    J Pept Sci; 2006 Dec; 12(12):800-7. PubMed ID: 17131293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology.
    Hayman WA; Toth I; Flinn N; Scanlon M; Good MF
    Immunol Cell Biol; 2002 Apr; 80(2):178-87. PubMed ID: 11940119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
    Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
    J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates.
    Abdel-Aal AB; Batzloff MR; Fujita Y; Barozzi N; Faria A; Simerska P; Moyle PM; Good MF; Toth I
    J Med Chem; 2008 Jan; 51(1):167-72. PubMed ID: 18072728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationship of lipid core peptide-based Group A Streptococcus vaccine candidates.
    Chan A; Hussein WM; Ghaffar KA; Marasini N; Mostafa A; Eskandari S; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Bioorg Med Chem; 2016 Jul; 24(14):3095-101. PubMed ID: 27246859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of conformational mimetics of conserved Streptococcus pyogenes minimal epitope as vaccine candidates.
    Zhong W; Skwarczynski M; Toth I
    Curr Drug Deliv; 2009 Oct; 6(5):520-7. PubMed ID: 19863488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship of group A streptococcus lipopeptide vaccine candidates in trimethyl chitosan-based self-adjuvanting delivery system.
    Nevagi RJ; Dai W; Khalil ZG; Hussein WM; Capon RJ; Skwarczynski M; Toth I
    Eur J Med Chem; 2019 Oct; 179():100-108. PubMed ID: 31247372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct.
    Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Indian J Med Res; 2004 May; 119 Suppl():88-94. PubMed ID: 15232170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus.
    Simerska P; Abdel-Aal AB; Fujita Y; Batzloff MR; Good MF; Toth I
    Biopolymers; 2008; 90(5):611-6. PubMed ID: 18381625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population.
    Zeng W; Horrocks KJ; Tan ACL; Wong CY; Chua BY; Jackson DC
    Vaccine; 2020 Jan; 38(3):597-607. PubMed ID: 31740096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A peptide carrier with a built-in vaccine adjuvant: construction of immunogenic conjugates.
    Krikorian D; Panou-Pomonis E; Voitharou C; Sakarellos C; Sakarellos-Daitsiotis M
    Bioconjug Chem; 2005; 16(4):812-9. PubMed ID: 16029022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity.
    Zaman M; Chandrudu S; Giddam AK; Reiman J; Skwarczynski M; McPhun V; Moyle PM; Batzloff MR; Good MF; Toth I
    Nanomedicine (Lond); 2014 Dec; 9(17):2613-24. PubMed ID: 25529566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.